Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688270 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
A Phase 2 study of Raynaud's Phenomenon Secondary to Connective Tissue Disease, sponsored by Covis Pharma S.à.r.l..
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT02688270: Completed Phase 2 study of Raynaud's Phenomenon Secondary to Connective Tissue Disease, sponsored by Covis Pharma S.à.r.l..
NCT02688270 is a Phase 2 study of Raynaud's Phenomenon Secondary to Connective Tissue Disease that has completed, run by Covis Pharma S.à.r.l.. The registered enrollment target is 65 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02688270, a Phase 2 study of Raynaud's Phenomenon Secondary to Connective Tissue Disease, has completed, sponsored by Covis Pharma S.à.r.l..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon. The symptoms of this disease include pain, tingling, and numbness in the fingers of the affected hand or hands.
Primary Outcome
Change from baseline to visit 6 in peak Main Raynaud's Symptom (MRS) severity. Raynaud's symptoms will be assessed separately using a 0 to100-mm Visual Analog Scale (VAS) for pain, numbness, and tingling where 0 mm = no symptom and 100 mm = most severe symptom.
Conditions Studied
Interventions
- DRUG Vascana (0.9% nitroglycerin cream)
- DRUG Vehicle Cream (placebo)
Study Locations (1)
Pennsylvania
- Multiple investigational sites - Multiple Locations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
What the finished NCT02688270 record still lists
NCT02688270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Raynaud's Phenomenon Secondary to Connective Tissue Disease appearing as the primary indexed condition, and to 2 interventions - of which Vascana (0.9% nitroglycerin cream) is the first listed.
NCT02688270 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02688270 about?
NCT02688270 is a clinical study titled "Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon". The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon. The symptoms of this disease include pain, tingling, and numbness in the fingers of the affected hand or hands.
What is the current status of trial NCT02688270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2016-06. Estimated completion is 2016-12.
What conditions does trial NCT02688270 study?
This clinical trial studies the following conditions: Raynaud's Phenomenon Secondary to Connective Tissue Disease.
What interventions are being tested in trial NCT02688270?
The interventions under investigation include: Vascana (0.9% nitroglycerin cream) (DRUG), Vehicle Cream (placebo) (DRUG).
Who is sponsoring clinical trial NCT02688270?
This trial is sponsored by Covis Pharma S.à.r.l., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02688270 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02688270's enrollment target sits among peer trials
65 987th of 2000 higher than 1,005 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia